Browsing Tag
Roche
92 posts
Major oncology milestone as Organon and Henlius secure FDA approval for POHERDY, the first U.S. biosimilar to PERJETA
Find out how FDA approval of POHERDY, the first U.S. biosimilar to PERJETA, may transform HER2-positive breast cancer treatment costs and patient access.
EirGenix signs global licensing deal with Sandoz for second HER2 biosimilar EG1206A
EirGenix signs a USD 152M global deal with Sandoz for its Perjeta biosimilar EG1206A after FDA/EMA nod. Find out what this means for the HER2 drug race.
Can Genentech’s $50 direct-to-patient Xofluza launch reshape access to flu antivirals in 2025?
Genentech slashes Xofluza price by 70% in a direct-to-patient launch with Amazon, Cost Plus, and Alto Pharmacy. See how this reshapes flu access in 2025.
Is Labcorp’s partnership with Roche the turning point for AI in cancer diagnostics?
Labcorp and Roche launch a digital pathology partnership to prepare diagnostics for AI—explore the market impact, stock sentiment, and industry risks.
Novo Nordisk seeks FDA nod for Mim8 — how will this impact hemophilia treatment and NVO stock?
Novo Nordisk files FDA application for Mim8 in hemophilia A. Learn how flexible dosing and trial data could redefine the bleeding disorder market.
The fibrosis frontier: Can anti-fibrotic drugs finally deliver where weight-loss therapies fall short?
Can anti-fibrotic drugs succeed where weight-loss therapies have stalled? Explore the future of MASH treatment and why fibrosis is the key clinical frontier.
89bio stock soars 85% as Roche seals $3.5bn takeover—What’s behind the surge and what’s next?
Roche is buying 89bio for up to $3.5B to add Phase 3 MASH drug pegozafermin. Find out what the CVR means and how investors should read the deal today.
Vabysmo shows 4-year durability in wet AMD and 60% lesion clearance in PCV: What the new Genentech data reveals
Genentech’s Vabysmo shows four years of vision durability in AMD and strong lesion control in PCV—see what’s next for this bispecific breakthrough.
Foresight Diagnostics strikes licensing deal with Roche for PhasED-Seq in non-Hodgkin’s lymphoma
Foresight Diagnostics licenses PhasED-Seq to Roche for Non-Hodgkin’s Lymphoma diagnostics, settling litigation and boosting precision oncology prospects.
Alnylam Pharmaceuticals (NASDAQ: ALNY) to launch global Phase 3 trial of RNAi therapy zilebesiran in high-risk hypertension patients
Alnylam Pharmaceuticals (NASDAQ: ALNY) moves its RNAi drug zilebesiran into a global Phase 3 trial for hypertension after ESC 2025 data showed sustained blood pressure reductions.